Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GH Research PLC - Ordinary Shares (NQ:GHRS)

13.26 +0.04 (+0.34%)
Streaming Delayed Price Updated: 2:20 PM EDT, Mar 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about GH Research PLC - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Why Is GHRS Stock Rising Today? ↗
GH Research stated that the FDA has cleared GH001 for a clinical investigation in the U.S. 
Via Stocktwits
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
GH Research Stock Grabs Retail Spotlight Ahead Of FDA Update On Depression Treatment ↗
GH001 showed symptom improvement, high remission rates, and sustained benefits in a Phase 2b trial for treatment-resistant depression. 
Via Stocktwits
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
GH Research PLC (NASDAQ:GHRS) Reports Q3 2025 Earnings Beat and Clinical Progress ↗
GH Research Q3 2025 results show a slight EPS beat. The biotech firm is focused on resolving the FDA clinical hold for its GH001 treatment for depression. 
Via Chartmill
Topics Earnings
News headline image
Depression-Focused GH Research Shares Could See Significant Upside: Analyst ↗
GH Research's GH001 shows strong Phase 2 results for treatment-resistant depression, with FDA issues nearly resolved and $1.9 billion U.S. potential. 
Via Benzinga
News headline image
This Monopar Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week ↗
These five small-cap pharma and biotech stocks drew heavy attention on Stocktwits last week, driven by key trial results, FDA updates, and promising drug developments. 
Via Stocktwits
News headline image
On Thursday, there are stocks with unusual volume. Let's take a look. ↗
Let's explore the current happenings on the US markets on Thursday. Below, you'll find the stocks exhibiting unusual volume in today's session. 
Via Chartmill
News headline image
These stocks have an unusual volume in today's session ↗
Discover the stocks with unexpected trading volume in today's session on the US markets. 
Via Chartmill
News headline image
Unusual volume stocks in Tuesday's session ↗
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look. 
Via Chartmill
News headline image
Crude Oil Moves Higher; Owens & Minor Shares Plummet ↗
 
Via Benzinga
News headline image
Dow Falls 150 Points; ISM Manufacturing PMI Rises In January ↗
 
Via Benzinga
Topics Stocks
News headline image
IDEXX Laboratories Posts Upbeat Results, Joins Stratasys, Saia And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Why Is GH Research Stock Trading Higher On Monday? ↗
GH Research's Phase 2b trial of GH001 for treatment-resistant depression met its primary endpoint, showing significant efficacy and a favorable safety profile. 
Via Benzinga
News headline image
S&P 500 Down Over 1%; Tyson Foods Posts Upbeat Results ↗
 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Triumph Group Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
3 Fast-Growing Stocks Analysts See Doubling in Price
Clinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches. 
Via MarketBeat
News headline image
Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week ↗
The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come. 
Via Talk Markets
News headline image
Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th ↗
While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are... 
Via Talk Markets
News headline image
Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August ↗
The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a... 
Via Talk Markets
News headline image
Irish Biotech Firm GH Research Sees Cash Decline in Q2, Advances Psychedelic Drug Trials ↗
Irish psychedelic biotech firm GH Research PLC (NASDAQ: GHRS) reported on Tuesday financial results for the second quarter ended June 30, 2024. Cash, cash equivalents, other financial assets and... 
Via Benzinga
News headline image
Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week ↗
Opportunities to invest in psychedelic stocks are emerging for those willing to get in early, and the 4 largest psychedelic compound-based portfolio drug discovery companies are up 5.9% in the past... 
Via Talk Markets
News headline image
Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD ↗
This article highlights the 4 largest market cap clinical-stage psychedelic compound-based drug discovery companies with their stock performances MTD, in July, their areas of focus, and their latest... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.